Delisting risk
BOLT · NASDAQ · Biotechnology

Bolt Biotherapeutics (BOLT)

Develops Boltbody immune-stimulating antibody conjugates for cancer.

$3.84
At close−0.23 (−5.65%)

Breakdown13F · 13D/G · Form 4

Institutions24 holders · as of Mar 31, 202631.84%613.3K shares
Insiders3 holders · as of Feb 4, 20262.21%42.6K shares
Otherremainder65.95%1.27M shares

1.93M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesEvidence
Sofinnova Investments, Inc.Institution
7.15%137,72113Fas of Mar 31, 2026
Renaissance Technologies LLCInstitution
4.01%77,22513Fas of Mar 31, 2026
Vivo Capital, LLCInstitution
3.76%72,41413Fas of Mar 31, 2026
Pivotal Bioventure Partners Investment Advisor LLCInstitution
2.21%42,58113Fas of Mar 31, 2026
Grant YonehiroInsiderofficer: Chief Operating Officer
2.02%38,918Form 4filed Oct 24, 2025
T3 Companies, LLCInstitution
1.97%38,00013Fas of Mar 31, 2026
Board of Trustees of the Leland Stanford Junior UniversityInstitution
1.87%35,97713Fas of Mar 31, 2026
Pfizer IncInstitution
1.63%31,30513Fas of Mar 31, 2026
LYNX1 Capital Management LPInstitution
1.60%30,80013Fas of Mar 31, 2026
Nan Fung Group Holdings LtdInstitution
1.52%29,25013Fas of Mar 31, 2026
Geode Capital Management, LLCInstitution
1.49%28,79113Fas of Mar 31, 2026
Nano Cap New Millennium Growth Fund L PInstitution
1.43%27,50013Fas of Mar 31, 2026
Shay Capital LLCInstitution
0.77%14,90513Fas of Mar 31, 2026
Susquehanna International Group, LLPInstitution
0.61%11,65713Fas of Mar 31, 2026
Citadel Advisors LLCInstitution
0.52%10,10913Fas of Mar 31, 2026
BlackRock, Inc.Institution
0.50%9,71113Fas of Mar 31, 2026
Vanguard Capital Management LLCInstitution
0.37%7,06013Fas of Mar 31, 2026
Morgan StanleyInstitution
0.17%3,18913Fas of Mar 31, 2026
Vanguard Fiduciary Trust CoInstitution
0.16%3,09513Fas of Mar 31, 2026
William P. QuinnInsiderdirector, officer: President, CEO and CFO
0.12%2,313Form 4filed Feb 4, 2026
Sarah NemecInsiderofficer: Senior VP, Finance and PAO
0.07%1,415Form 4filed Feb 4, 2026
Tower Research Capital LLC (TRC)Institution
0.06%1,09313Fas of Mar 31, 2026
UBS Group AGInstitution
0.04%78713Fas of Mar 31, 2026
JPMorgan Chase & CoInstitution
0.00%4213Fas of Mar 31, 2026
Vanguard Global Advisers, LLCInstitution
0.00%2413Fas of Mar 31, 2026

13F — a manager's quarterly holdings · Form 4 — an insider's transaction report

Institutions13F, as of Mar 31, 2026

24 holders · 613.3K shares · 6 new positions · 12 increased · 3 reduced · 3 closed

HolderShares% outstandingChg q/qFiled
Sofinnova Investments, Inc.137.7K7.15%0May 15, 2026
Renaissance Technologies LLC77.2K4.01%+22.2KMay 14, 2026
Vivo Capital, LLC72.4K3.76%0May 20, 2026
Pivotal Bioventure Partners Investment Advisor LLC42.6K2.21%−52.0KMay 14, 2026
T3 Companies, LLC38.0K1.97%0May 7, 2026
Board of Trustees of the Leland Stanford Junior University36.0K1.87%0May 7, 2026
Pfizer Inc31.3K1.63%0May 12, 2026
LYNX1 Capital Management LP30.8K1.60%+30.8KnewMay 4, 2026

Ownership statements13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Tang Capital Management, LLC9.90%13GMay 15, 2025
Renaissance Technologies LLC5.13%98.6K13GAug 13, 2026

Insider tradesForm 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Dec 5, 2025
Sarah Nemecofficer: Senior VP, Finance and PAO
Purchase125$4.611,415
Dec 5, 2025
William P. Quinndirector, officer: President, CEO and CFO
Purchase125$4.612,313
Jun 6, 2025
William P. Quinndirector, officer: President, CEO and CFO
Purchase125$5.492,188
Jun 6, 2025
Sarah Nemecofficer: Senior VP, Finance and PAO
Purchase125$5.49943

CongressHouse and Senate disclosures

Not reported.